146 related articles for article (PubMed ID: 32004727)
1. Advancing serum peptidomic profiling by data-independent acquisition for clear-cell renal cell carcinoma detection and biomarker discovery.
Lin L; Zheng J; Zheng F; Cai Z; Yu Q
J Proteomics; 2020 Mar; 215():103671. PubMed ID: 32004727
[TBL] [Abstract][Full Text] [Related]
2. High throughput and accurate serum proteome profiling by integrated sample preparation technology and single-run data independent mass spectrometry analysis.
Lin L; Zheng J; Yu Q; Chen W; Xing J; Chen C; Tian R
J Proteomics; 2018 Mar; 174():9-16. PubMed ID: 29278786
[TBL] [Abstract][Full Text] [Related]
3. Identification of potential serum proteomic biomarkers for clear cell renal cell carcinoma.
Yang J; Yang J; Gao Y; Zhao L; Liu L; Qin Y; Wang X; Song T; Huang C
PLoS One; 2014; 9(11):e111364. PubMed ID: 25368985
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive peptidome profiling technology for the identification of early detection biomarkers for lung adenocarcinoma.
Ueda K; Saichi N; Takami S; Kang D; Toyama A; Daigo Y; Ishikawa N; Kohno N; Tamura K; Shuin T; Nakayama M; Sato TA; Nakamura Y; Nakagawa H
PLoS One; 2011 Apr; 6(4):e18567. PubMed ID: 21533267
[TBL] [Abstract][Full Text] [Related]
5. Alterations of the serum peptidome in renal cell carcinoma discriminating benign and malignant kidney tumors.
Gianazza E; Chinello C; Mainini V; Cazzaniga M; Squeo V; Albo G; Signorini S; Di Pierro SS; Ferrero S; Nicolardi S; van der Burgt YE; Deelder AM; Magni F
J Proteomics; 2012 Dec; 76 Spec No.():125-40. PubMed ID: 22868251
[TBL] [Abstract][Full Text] [Related]
6. Urinary RKIP/p-RKIP is a potential diagnostic and prognostic marker of clear cell renal cell carcinoma.
Papale M; Vocino G; Lucarelli G; Rutigliano M; Gigante M; Rocchetti MT; Pesce F; Sanguedolce F; Bufo P; Battaglia M; Stallone G; Grandaliano G; Carrieri G; Gesualdo L; Ranieri E
Oncotarget; 2017 Jun; 8(25):40412-40424. PubMed ID: 28418894
[TBL] [Abstract][Full Text] [Related]
7. Data-Independent Acquisition-Based Quantitative Proteomic Analysis Reveals Potential Biomarkers of Kidney Cancer.
Song Y; Zhong L; Zhou J; Lu M; Xing T; Ma L; Shen J
Proteomics Clin Appl; 2017 Dec; 11(11-12):. PubMed ID: 28975715
[TBL] [Abstract][Full Text] [Related]
8. MALDI-TOF peptidomic analysis of serum and post-prostatic massage urine specimens to identify prostate cancer biomarkers.
Padoan A; Basso D; Zambon CF; Prayer-Galetti T; Arrigoni G; Bozzato D; Moz S; Zattoni F; Bellocco R; Plebani M
Clin Proteomics; 2018; 15():23. PubMed ID: 30065622
[TBL] [Abstract][Full Text] [Related]
9.
Lin W; Chen X; Chen T; Liu J; Ye Y; Chen L; Qiu X; Chia-Hsien Cheng J; Zhang L; Wu J; Qiu S
DNA Cell Biol; 2020 Jun; 39(6):1000-1011. PubMed ID: 32282241
[TBL] [Abstract][Full Text] [Related]
10. Data-Independent Acquisition of HLA Class I Peptidomes on the Q Exactive Mass Spectrometer Platform.
Ritz D; Kinzi J; Neri D; Fugmann T
Proteomics; 2017 Oct; 17(19):. PubMed ID: 28834231
[TBL] [Abstract][Full Text] [Related]
11. Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.
Reustle A; Di Marco M; Meyerhoff C; Nelde A; Walz JS; Winter S; Kandabarau S; Büttner F; Haag M; Backert L; Kowalewski DJ; Rausch S; Hennenlotter J; Stühler V; Scharpf M; Fend F; Stenzl A; Rammensee HG; Bedke J; Stevanović S; Schwab M; Schaeffeler E
Genome Med; 2020 Mar; 12(1):32. PubMed ID: 32228647
[TBL] [Abstract][Full Text] [Related]
12. Development and confirmation of potential gene classifiers of human clear cell renal cell carcinoma using next-generation RNA sequencing.
Eikrem OS; Strauss P; Beisland C; Scherer A; Landolt L; Flatberg A; Leh S; Beisvag V; Skogstrand T; Hjelle K; Shresta A; Marti HP
Scand J Urol; 2016 Dec; 50(6):452-462. PubMed ID: 27739342
[TBL] [Abstract][Full Text] [Related]
13. Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target.
Chen D; Chen W; Xu Y; Zhu M; Xiao Y; Shen Y; Zhu S; Cao C; Xu X
J Med Genet; 2019 Jan; 56(1):43-49. PubMed ID: 29967134
[TBL] [Abstract][Full Text] [Related]
14. Tumor size, stage and grade alterations of urinary peptidome in RCC.
Chinello C; Cazzaniga M; De Sio G; Smith AJ; Grasso A; Rocco B; Signorini S; Grasso M; Bosari S; Zoppis I; Mauri G; Magni F
J Transl Med; 2015 Oct; 13():332. PubMed ID: 26482227
[TBL] [Abstract][Full Text] [Related]
15. Advancing Urinary Protein Biomarker Discovery by Data-Independent Acquisition on a Quadrupole-Orbitrap Mass Spectrometer.
Muntel J; Xuan Y; Berger ST; Reiter L; Bachur R; Kentsis A; Steen H
J Proteome Res; 2015 Nov; 14(11):4752-62. PubMed ID: 26423119
[TBL] [Abstract][Full Text] [Related]
16. MicroRNAs in Serum Exosomes as Potential Biomarkers in Clear-cell Renal Cell Carcinoma.
Zhang W; Ni M; Su Y; Wang H; Zhu S; Zhao A; Li G
Eur Urol Focus; 2018 Apr; 4(3):412-419. PubMed ID: 28753793
[TBL] [Abstract][Full Text] [Related]
17. Long Non-Coding RNA LUCAT1 Promotes Proliferation and Invasion in Clear Cell Renal Cell Carcinoma Through AKT/GSK-3β Signaling Pathway.
Zheng Z; Zhao F; Zhu D; Han J; Chen H; Cai Y; Chen Z; Xie W
Cell Physiol Biochem; 2018; 48(3):891-904. PubMed ID: 30032137
[TBL] [Abstract][Full Text] [Related]
18. The Peptidome Comes of Age: Mass Spectrometry-Based Characterization of the Circulating Cancer Peptidome.
Greening DW; Kapp EA; Simpson RJ
Enzymes; 2017; 42():27-64. PubMed ID: 29054270
[TBL] [Abstract][Full Text] [Related]
19. Development of data-independent acquisition workflows for metabolomic analysis on a quadrupole-orbitrap platform.
Zhou J; Li Y; Chen X; Zhong L; Yin Y
Talanta; 2017 Mar; 164():128-136. PubMed ID: 28107906
[TBL] [Abstract][Full Text] [Related]
20. The Strategy for Peptidomic LC-MS/MS Data Analysis: The Case of Urinary Peptidome Study.
Zakharova NV; Bugrova AE; Indeykina MI; Brzhozovskiy AG; Nikolaev EN; Kononikhin AS
Methods Mol Biol; 2024; 2758():389-399. PubMed ID: 38549026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
